NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

Anbio Biotechnology (NNNN) Stock Analysis

Anbio Biotechnology (NNNN) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

NNNN

$6.54

−$0.06 (−0.91%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare NNNN with… →

NNNN Key Statistics

As of Sep 4, 2026
Trading
Open
$6.58
Previous Close
$6.60
Day's Range
6.36–6.77
52-Week Range
6.28–51.33
Volume
231.10K
Valuation
Market Cap
$287.05M
P/E Ratio
43.60
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
33.20
EPS (ttm)Profit attributable to each share over the last twelve months.
0.15
Financials (FY)
Revenue (FY)
$8.65M+5.64%
Net Income (FY)
$6.40M+169.86%
Profit marginThe share of revenue left as profit after all costs and taxes.
74.06%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
43.89M
1-Year Return
−86.27%
Dividend and dates
Avg Volume
99.87K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

NNNN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−78.25%
2025 (partial year)+421.14%

As of September 4, 2026.

NNNN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$8.65M$6.40M74.1%
2024$8.19M$2.37M29.0%
2023$6.71M$2.25M33.6%
2022$23.54M$10.01M42.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.65M$7.54M$5.77M$6.40M74.1%
2024$8.19M$5.89M$2.00M$2.37M29.0%
2023$6.71M$3.36M$1.96M$2.25M33.6%
2022$23.54M$12.56M$10.20M$10.01M42.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

NNNN Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricNNNNMedical Instruments & Supplies medianvs median
P/E43.6035.6122% above
P/S ratio33.203.1710.5x the median
Profit margin74.06%0.85%73.2 pts above

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Anbio Biotechnology (NNNN) carries a market capitalisation of $287.05M. It is classified in the Medical Instruments & Supplies industry, within the Healthcare sector. Headcount on file is 27.

The 52-week range on file runs from $6.28 to $51.33. The most recent close on file for NNNN is $6.54, dated September 4, 2026. That is −$0.06 (−0.91%) against the previous close. The latest close sits 4.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $8.65M. Against the prior fiscal year total of $8.19M, that is a change of +5.64%. The same year closed with net income of $6.40M. That is +169.86% against the prior fiscal year. The reported profit margin is 74.06%. That is 73.2 percentage points above the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to 0.15.

Across the 4 fiscal years on file, revenue moves from $23.54M in 2022 to $8.65M in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

NNNN trades at a trailing price-to-earnings ratio of 43.6. That is 22.42% above the Medical Instruments & Supplies median of 35.61. The price-to-sales ratio is 33.2. On price-to-sales that is 10.5 times the Medical Instruments & Supplies median of 3.17. The medians here are taken across 55 Medical Instruments & Supplies companies that report the metric.

Over the trailing twelve months the price has returned −86.27%. The stored price history starts on February 19, 2025, and the total return since then is +13.34%. Daily returns over the trailing 1 year annualize to a volatility of 142.86%.

Growth & Income

The record shows no dividend for NNNN.

2026 is still running; the price is −78.25% year to date.

Peer Comparison

Anbio Biotechnology (NNNN) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Anbio Biotechnology NNNN $287.05M 43.6
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. Anbio Biotechnology trades at a P/E of 43.6.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Anbio Biotechnology

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Visit website →